Patient and tumor characteristics of the 1,090 patients in relation to daily coffee consumption (cups/day)
| All | Low (0–1) | Moderate (2–4) | High (5+) | ||
|---|---|---|---|---|---|
| (n = 1,090) | (n = 202) | (n = 668) | (n = 220) | Ptrend | |
| Patient characteristics, median (IQR) | |||||
| Age at diagnosis, y | 61.2 (52.1–68.1) | 59.4 (48.6–67.8) | 62.7 (55.0–69.3) | 58.6 (49.5–65.6) | >0.3a |
| Weight (kg) | 69.0 (62.0–78.0) | 68.0 (60.0–74.6) | 70.0 (62.0–79.0) | 69.2 (61.0–79.0) | >0.3a |
| Missing | 36 | 8 | 18 | 10 | |
| Height (m) | 1.65 (1.62–1.70) | 1.65 (1.61–1.69) | 1.65 (1.62–1.70) | 1.67 (1.63–1.70) | >0.3a |
| Missing | 36 | 8 | 18 | 10 | |
| BMI (kg/m2) | 25.1 (22.5–28.4) | 24.5 (21.9–27.7) | 25.2 (22.8–28.6) | 25.0 (22.6–27.9) | >0.3a |
| Missing | 38 | 8 | 20 | 10 | |
| Waist-to-hip ratio | 0.86 (0.81–0.91) | 0.86 (0.81–0.90) | 0.86 (0.81–0.90) | 0.87 (0.82–0.91) | >0.3a |
| Missing | 53 | 13 | 23 | 17 | |
| Total breast volume (mL) | 1,000 (650–1,500) | 925 (550–1,463) | 1,000 (700–1,600) | 950 (600–1,400) | >0.3a |
| Missing | 178 | 36 | 101 | 41 | |
| Age at first full-term pregnancy (y) | 25.0 (22.0–28.0) | 26.0 (23.0–29.0) | 24.0 (21.0–28.0) | 24.0 (21.0–28.0) | 0.009a |
| Missing | 140 | 33 | 85 | 22 | |
| Current smoker, n (%) | 219 (20.1%) | 18 (8.9%) | 119 (17.8%) | 82 (37.3%) | <0.001b |
| Missing | 4 | 1 | 3 | 0 | |
| Alcohol abstainer, n (%) | 116 (10.6%) | 33 (16.3%) | 70 (10.5%) | 13 (5.9%) | 0.001b |
| Missing | 3 | 0 | 2 | 1 | |
| Tumor characteristics, n (%) | |||||
| Invasive tumor size (pT) | |||||
| 1 | 785 (72.0%) | 134 (66.3%) | 485 (72.6%) | 166 (75.5%) | 0.013b |
| 2 | 287 (26.3%) | 60 (29.7%) | 175 (26.2%) | 52 (23.6%) | |
| 3 | 16 (1.5%) | 8 (4.0%) | 6 (0.9%) | 2 (0.9%) | |
| 4 | 2 (0.2%) | 0 | 2 (0.3%) | 0 | |
| Node status | |||||
| 0 | 668 (61.4%) | 116 (57.7%) | 419 (62.8%) | 133 (60.5%) | >0.3b |
| 1–3 | 326 (30.0%) | 65 (32.3%) | 192 (28.8%) | 69 (31.4%) | |
| 4+ | 94 (8.6%) | 20 (10.0%) | 56 (8.4%) | 18 (8.2%) | |
| Missing (n) | 2 | 1 | 1 | 0 | |
| Histologic grade | |||||
| 1 | 266 (24.4%) | 43 (21.3%) | 167 (25.0%) | 56 (25.5%) | >0.3b |
| 2 | 540 (49.6%) | 110 (54.5%) | 324 (48.6%) | 106 (48.2%) | |
| 3 | 283 (26.0%) | 49 (24.3%) | 176 (26.4%) | 58 (26.4%) | |
| Missing (n) | 1 | 0 | 1 | 0 | |
| Ki67 | |||||
| Negative/low (≤20%) | 300 (63.0%) | 63 (63.0%) | 173 (62.0%) | 64 (66.0%) | >0.3b |
| High (>20%) | 176 (37.0%) | 37 (37.0%) | 106 (38.0%) | 33 (34.0%) | |
| Missing (n) | 614 | 102 | 389 | 123 | |
| Hormone receptor status | |||||
| ER+ | 956 (87.9%) | 185 (91.6%) | 586 (88.1%) | 185 (84.1%) | 0.018b |
| ER− | 131 (12.1%) | 17 (8.4%) | 79 (11.9%) | 35 (15.9%) | |
| Missing (n) | 3 | 0 | 3 | 0 | |
| PgR+ | 774 (71.2%) | 139 (68.8%) | 483 (72.6%) | 152 (69.1%) | >0.3b |
| PgR− | 313 (28.8%) | 63 (31.2%) | 182 (27.4%) | 68 (30.9%) | |
| Missing (n) | 3 | 0 | 3 | 0 | |
| ER+PgR+ | 767 (70.6%) | 138 (68.3%) | 479 (72%) | 150 (68.2%) | >0.3b |
| ER+PgR− | 189 (17.4%) | 47 (23.3%) | 107 (16.1%) | 35 (15.9%) | 0.052b |
| ER−PgR− | 124 (11.4%) | 16 (7.9%) | 75 (11.3%) | 33 (15.0%) | 0.022b |
| ER−PgR+ | 7 (0.6%) | 1 (0.5%) | 4 (0.6%) | 2 (0.9%) | >0.3b |
| Missing (n) | 3 | 0 | 3 | 0 | |